About Guard Medical
Our goal is to reduce Surgical Site Infections (SSI) and improve patient care whilst providing considerable savings to the healthcare system.
Guard Medical is the developer of NPseal™. We are an innovation driven company focused on creating easy-to-use and cost-effective solutions that enable prophylactic NPWT wound care of closed surgical incisions.
Guard Medical Team
Machiel van der Leest
President & Founder
Machiel is a seasoned medical device professional and entrepreneur. He has developed and introduced over 10 class III devices in the interventional cardio- and neurovascular market. In his 20+ year career Machiel held executive positions as CTO, CSO and CEO. Prior to Guard Medical he was CEO of ART – bioresorbable stent. Machiel has raised funds and closed deals with an aggregated value of over €100 million. He holds a MSc degree from the Technical University Delft and is an inventor on 25+ patents.
Dr. Frederick Cornhill
CSO & Founder
Frederick has spent 40+ years working in MedTech start-ups both academic and commercial. He was the founding Chairman of Ohio State’s Biomedical Engineering (BME) Center, Cleveland Clinic’s Department of BME and Oxford University’s Institute of BME. Most recently, he was the Co-Director of the Minimally Invasive New Technology Program at New York Presbyterian and Weill Cornell Medical Center. He received his doctorate from the University of Oxford in BME, has authored over 100 scientific articles and is an inventor on 40+ patents.
Laurence Lefebvre
COO & Founder
Laurence has 20+ years of experience in the development of medical technologies. Starting her career in medical imaging, she worked at Bain & Company focusing in healthcare before joining the Minimally Invasive New Technology Program. Most recently, she was a senior director at Lumendi leading the development of new devices in the GI field. Laurence holds a MSc in Bioengineering from Imperial College London and a MBA from Harvard Business School and is an inventor on 10+ patents.
Sang Lee, MD
Founder
Sang is the Chief of Colon and Rectal Surgery at University of Southern California / Keck School of Medicine. Sang is one of the nation’s leading experts in laparoscopic colorectal and endoluminal surgeries. He has authored more than 75 original articles on colon and rectal surgery in peer-reviewed journals. Sang graduated from Johns Hopkins University with degree in biomedical engineering and obtained medical degree from New York University School of Medicine.
Board of Directors
Philippe Boucheron
Philippe has over twenty years of life science investment experience. He is a Deputy Chief of Life Sciences Investment at Bpifrance and serves on boards of Ademtech, GamaMabs, Advicenne, NH TherAguix, Limflow and Corwave. He holds an MBA from INSEAD.
Philippe Dhamelincourt
Philippe is co-founder and Chairman of Matignon Investissement & Gestion. Philippe has been active in venture capital investment for nearly 40 years. After Arthur Andersen and SIMER, Philippe joined the Worms Bank in 1978 and became CEO of ACMER.
Phil Cooper
Phil has more than 30 years of experience in the medical device industry. Phil was President of Molnlycke Wound Care from 2007 to 2014 Phil is a non-executive director for listed LiDCO Group PLC, Alesi Surgical Limited and Soest Medical Group (NLD).
Thierry Sarda
Thierry has over 25 years of experience in the medical device industry in sales, marketing and general management. Thierry designed and lead major transformation programs in various healthcare sectors from hospital to homecare, in France and Europe.
Partners
